

IMMUNOMEDICS INC  
Form 8-K  
June 17, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 11, 2010

Immunomedics, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	000-12104 (Commission File Number)	61-1009366 (IRS Employer Identification No.)
---	---------------------------------------	---

300 American Road, Morris Plains, New Jersey (Address of Principal Executive Offices)	07950 (Zip Code)
--	---------------------

(973) 605-8200  
(Registrant's telephone number,  
including area code)

Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed on May 3, 2010, Dr. Edward T. Wolynic had informed Immunomedics, Inc. (the “Company”) of his intention not to stand for re-election at the Company’s next Annual Meeting of Stockholders, scheduled to be held in December 2010. However, due to an increase in demand for his consulting and advisory services, on June 11, 2010, Dr. Wolynic informed the Company that his resignation will now be effective as of June 14, 2010. Dr. Wolynic has also informed the Company that his resignation is not due to any disagreement between Dr. Wolynic and the Company on any matter relating to the Company’s operations, policies or practices.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.

By: /s/ Cynthia L. Sullivan  
Name: Cynthia L. Sullivan  
Title: President and Chief Executive Officer

Date: June 17, 2010